Related Experiment Videos
[Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice]
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China.
Aim:
To study the antitumor activity of sobuzoxane (Sob) in combination with doxorubicin (Dox) and the effect of Sob on Dox-induced cardiotoxicity.
Methods:
DBA/2 mice bearing transplanted leukemia P388 were given i.v. Dox 2 mg.kg-1.d-1 for 3 d, 4 mg.kg-1.d-1 for 1 d combined with ig Sob 20, 40 mg.kg-1.d-1 for 7 d. The increase in life span (ILS) of each group was recorded in 30 d. The myocardium of moribund mice was examined by transmission electron microscopy.
Results:
The ILS of combination therapeutic groups of Sob with Dox was 48.7%, 57.3%, 59.0%, and 62.4% respectively, which were 30%-90% higher than the sum of ILS of two groups treated with Dox and Sob separately (P < 0.01). The ultrastructural injury of cardiomyocytes of P388-bearing mice caused by combination chemotherapy with Dox plus Sob was markedly attenuated compared with Dox alone.
Conclusion:
Sob with Dox exhibited an antitumor synergistic effect on leukemia P388, and the cardiotoxicity of Dox was reduced by Sob.